EG 427

EG 427 is a French biotechnology company that specializes in a novel approach to gene therapy known as pinpoint gene therapy. The company focuses on developing HSV-1-based vectors, leveraging the natural characteristics of Herpes Simplex Virus 1 to create targeted and long-lasting expression of therapeutic genes. This innovative method aims to address spinal cord injury-related disorders, particularly neurogenic bladder conditions, by providing physicians with a potential cure for patients suffering from severe, chronic, and localized diseases. Through its advanced research, EG 427 seeks to transform treatment options for individuals affected by these challenging medical issues.